Fenwal, Inc.

Fenwal, Inc., a foreign-owned for-profit subsidiary of Fresenius Kabi headquartered in Lake Zurich, Illinois, supplies specialized blood collection, separation, storage, and transfusion products and consumables to federal health agencies as a prime contractor competing under full-and-open procurement with no set-aside posture. The company operates across pharmaceutical preparation manufacturing (NAICS 325412), surgical and medical instrument manufacturing (NAICS 339112), and surgical appliance and supplies manufacturing (NAICS 339113), with federal procurement anchored to medical supply and blood products delivery across PSC codes for Drugs and Biologicals (674 awards) and Medical and Surgical Instruments, Equipment, and Supplies (499 awards).

Fenwal's federal customer base concentrates heavily in military and defense health operations. The Department of the Navy Bureau of Medicine and Surgery leads by combined potential value at $8.2 million across 144 awards, followed by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 at $3.6 million across 16 awards; however, the Defense Logistics Agency Troop Support Medical dominates by award count with 872 orders collectively valued at $3 million, reflecting a high-volume small-purchase model. The National Institutes of Health Clinical Center (36 awards, $1.5 million) and Defense Health Agency (24 awards, $2.4 million) round out the active customer set across 17 distinct federal agencies. The 80% coverage by the top five customers indicates moderate concentration, with the Navy's dollar dominance offset by DLA's operational breadth.

Representative contract work demonstrates Fenwal's core blood-supply role. A $645.972 million sole-source definitive contract from the VA's Veterans Integrated Service Network 12, awarded October 2, 2024, procures military blood bags, glycerolyte solution, sodium chloride solution, and related blood-processing consumables for the Capt. James A. Lovell Federal Healthcare Center in North Chicago. A $255.011 million sole-source purchase order from the Defense Health Agency, awarded August 22, 2023, supplied two Amicus Apheresis Separators with related consumables and installation to US Naval Hospital Okinawa. Fenwal holds two named parent IDCs with the Department of the Navy (N6264509D5027 and N6264514D5050) carrying 51 task orders combined valued at $1.633 million. Smaller routine purchase orders dominate the award pattern—hundreds of orders under $10,000 for washing solutions, diluting solutions, anticoagulant citrate products, blood collection assemblies, donor tubing strippers, centrifuging bags, plasma extractors, and blood pack sealers flowing to DLA's Medical Supply Chain and military treatment facilities worldwide.

Fenwal operates exclusively as a prime contractor with no subcontract footprint in the source data (100% prime, 0% sub split across 1,400 total awards). Activity has remained relatively flat year over year—73 awards in 2022, declining to 65 in 2024, then recovering to 69 in 2025, with 20 awards recorded in the first seven months of 2026. The recompete cliff presents minimal near-term risk: only three awards with combined potential value of $371 thousand reach ultimate completion inside the next twenty-four months. Federal vendor registration dates to April 3, 2007. Combined potential value across all awards stands at $22.5 million with $19.2 million already obligated (85% execution rate), reflecting the mature, operational nature of Fenwal's federal blood-supply positioning. The company faces no set-aside competition and competes on specialized-source and sole-source authority (FAR 6.302-1 language appears in multiple VA and DHA awards), anchoring its federal role to the absence of meaningful commercial or government alternatives in transfusion medicine and apheresis equipment consumables.